• About us
• Contact

Advertisement

Organisation › Details

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston'sInnovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for nine years in a row. *

 

	Start	1998-02-21 existent
	End	1998-02-21 existent
	Group	Vertex Pharmaceuticals (Group)
	Industry	pharmaceutical
	Person	Leiden, Jeffrey M. (Vertex 20212– CEO before Clarus Ventures + Abbott)
	Region	Boston, MA
	Country	United States (USA)
	Street	50 Northern Avenue
	City	02210 Boston, MA
	Tel	+1-617-341-6100
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	199,012,000 (revenues, total, consolidated (2007) 2007-12-31)
	Profit	-391,279,000 (2007-12-31)
	Cash	467,796,000 (2007-09-30)
		* Document for »About Section«: Vertex Pharmaceuticals Inc.. (6/6/19). "Press Release: Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics". Boston, MA & Watertown,
		Record changed: 2023-07-10

Advertisement

More documents for Vertex Pharmaceuticals (Group)

• [1] CRISPR Therapeutics AG. (4/3/23). "Press Release: CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalas...
• [2] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....
• [3] CRISPR Therapeutics AG. (2/21/23). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results". Zug & Boston, MA....
• [4] CRISPR Therapeutics AG. (10/28/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results". Zug & Cambridge, MA....
• [5] CRISPR Therapeutics AG. (5/11/20). "Press Release: CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies". Zug, Cambridge, MA...
• [6] CRISPR Therapeutics AG. (2/12/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results". Zug & Cambridge, MA....
• [7] CRISPR Therapeutics AG. (11/19/19). "Press Release: CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies". Zug...
• [8] Vertex Pharmaceuticals Inc.. (6/6/19). "Press Release: Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics". Boston, MA & Watertown,...
• [9] CRISPR Therapeutics AG. (4/29/19). "Press Release: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results". Zug & Cambridge, MA....
• [10] CRISPR Therapeutics AG. (2/25/19). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results". Zug & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.